Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Daniel R. Omstead net worth and biography

Daniel Omstead Biography and Net Worth

President of Abrdn Life Sciences Investors

Dan Omstead is President of TCM and the Funds. Dr. Omstead joined TCM in October 2000. Previously, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc., a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson & Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, he participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dr. Omstead holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.

Dr. Omstead is a member of the team responsible for making investments on behalf of the Funds and has overall investment decision responsibility. Dr. Omstead has over nineteen years of investment experience.

What is Daniel R. Omstead's net worth?: The estimated net worth of Daniel R. Omstead is at least $2.41 million as of September 25th, 2023. Dr. Omstead owns 178,269 shares of Abrdn Life Sciences Investors stock worth more than $2,406,632 as of December 22nd. This net worth evaluation does not reflect any other investments that Dr. Omstead may own. Learn More about Daniel R. Omstead's net worth.
How old is Daniel R. Omstead?: Dr. Omstead is currently 71 years old. Learn More on Daniel R. Omstead's age.
How do I contact Daniel R. Omstead?: The corporate mailing address for Dr. Omstead and other Abrdn Life Sciences Investors executives is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. Abrdn Life Sciences Investors can also be reached via phone at (617) 772-8500 and via email at [email protected]. Learn More on Daniel R. Omstead's contact information.
Has Daniel R. Omstead been buying or selling shares of Abrdn Life Sciences Investors?: Daniel R. Omstead has not been actively trading shares of Abrdn Life Sciences Investors over the course of the past ninety days. Learn More on Daniel R. Omstead's trading history.
Who are Abrdn Life Sciences Investors' active insiders?: Abrdn Life Sciences Investors' insider roster includes Kathleen Goetz (Director), and Daniel Omstead (President). Learn More on Abrdn Life Sciences Investors' active insiders.
Are insiders buying or selling shares of Abrdn Life Sciences Investors?: In the last year, Abrdn Life Sciences Investors insiders bought shares 23 times. They purchased a total of 464,463 shares worth more than $6,200,962.27. The most recent insider tranaction occured on August, 23rd when Director Bill Maher bought 650 shares worth more than $9,990.50. Insiders at Abrdn Life Sciences Investors own 10.1% of the company. Learn More about insider trades at Abrdn Life Sciences Investors.
Information on this page was last updated on 8/23/2024.

Daniel R. Omstead Insider Trading History at Abrdn Life Sciences Investors

Daniel R. Omstead Buying and Selling Activity at Abrdn Life Sciences Investors

Abrdn Life Sciences Investors Company Overview

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Today's Range

Now: $13.50

$13.16

$13.54

50 Day Range

MA: $14.45

$13.15

$15.25

2 Week Range

Now: $13.50

$12.76

$15.90

Volume

94,492 shs

Average Volume

93,448 shs

Market Capitalization

$369.24 million

P/E Ratio

N/A

Dividend Yield

13.94%

Beta

0.71

First JFK… next Elon?

From Porter & Company | Ad